A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Trial Details

NCT ID

NCT04303988

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• SHR-1316
• Bevacizumab
• Cisplatin/Carboplatin

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Age ≥ 18 years old, and ≤ 70 years old, both genders;
• ECOG performance status 0-2;
• Pathological tests confirm HR-negative / HER2-negative breast cancer; there is evidence of local recurrence or metastasis；not suitable with curativ…
• It is required that no platinum drugs have been used before, or platinum drugs have been used (cisplatin/carboplatin only one regimen) and platinum…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.